Ascentage Pharma appoints Marina S. Bozilenko and Debra Yu as Independent Directors
Ascentage Pharma has exciting news to share! They’ve appointed two new independent non-executive directors, Ms. Marina S. Bozilenko and Dr. Debra Yu, to join their team starting November 25, 2024. This addition is a big step for Ascentage Pharma as they continue to make strides with their global innovation strategy.
Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma, expressed his warm welcome to the new directors, highlighting their extensive experience in finance, investment, business development, and strategic management within the global biopharmaceutical industry. He emphasized how crucial this moment is for Ascentage Pharma and how the new directors will bring valuable insights and strategic acumen to drive the company’s growth forward.
Ms. Marina S. Bozilenko has an impressive background as the President, CEO, and Director at Biothea Pharma, and she’s also been an independent director at Talphera, Inc. Her career includes roles at renowned firms such as William Blair & Co. LLC and Bear, Stearns & Co., Inc. Ms. Bozilenko’s expertise spans multiple domains, making her a valuable addition to the board.
Dr. Debra Yu, MD, brings a wealth of experience as the Chief Operating Officer and partner at Panacea Venture. She also serves on the board of MeiraGTx Holdings PLC and is an independent non-executive director at JW (Cayman) Therapeutics Co. Ltd. Dr. Yu’s background includes leadership roles at LianBio and Pfizer, showcasing her diverse expertise in healthcare investment and strategy.
Ascentage Pharma, a global biopharmaceutical company focused on addressing unmet medical needs in malignancies, is known for its innovative drug candidates targeting key pathways related to cancer. The company’s commitment to R&D and strategic partnerships with industry leaders has positioned them as a frontrunner in the biopharmaceutical space.
By continuously strengthening their R&D capabilities and expanding their clinical development programs, Ascentage Pharma aims to make a meaningful impact on patient care both in China and around the world. The appointment of Ms. Bozilenko and Dr. Yu as independent non-executive directors signifies the company’s dedication to driving innovation and growth in the biopharmaceutical sector.
